Haleon (HLN) EBIT Margin (2021 - 2023)

Haleon (HLN) posted EBIT Margin of 20.21% for Q4 2023, up 8.2% on a QoQ basis from 18.68% in Q2 2023, and down 3571.0% year-over-year from 0.58% in Q4 2022.

Haleon (HLN) EBIT Margin (2021 - 2023) Analysis & Trends

Haleon's EBIT Margin history runs 3 years deep, the most recent figure standing at 20.21% for Q4 2023.

  • Quarterly EBIT Margin fell 3571.0% year-over-year to 20.21% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 25.39% (changed N/A YoY) and the FY2025 annual result came in at 21.87%, up 223.0% from the prior year.
  • EBIT Margin was 20.21% for Q4 2023 at Haleon, up from 18.68% in the prior quarter.
  • Across five years, EBIT Margin topped out at 55.92% in Q4 2022 and bottomed at 17.61% in Q4 2021.
  • A 3-year average of 26.68% and a median of 20.21% in 2023 frame the typical range for EBIT Margin.
  • Annual changes were most pronounced in 2022 — EBIT Margin jumped 3831 bps — and 2023, when it slumped 3571 bps.
  • Haleon's EBIT Margin stood at 17.61% in 2021, then surged by 218 bps to 55.92% in 2022, then tumbled by 64 bps to 20.21% in 2023.
  • Business Quant data shows HLN's EBIT Margin at 20.21% in Q4 2023, 18.68% in Q2 2023, and 21.0% in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 16.37%
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 36.83%
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -38.02%
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 41.69%
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -2.27%
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 23.74%
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 21.23%
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 8.47%

Historic Data

Download Data
DateValue
Dec 31, 2023 20.21%
Jun 30, 2023 18.68%
May 3, 2023 21.00%
Dec 31, 2022 55.92%
Dec 31, 2021 17.61%